Acute myeloid leukemia: open trials in Finland

12 open trials have a site in Finland. Registry data; only the trial team decides who can take part.

NCT07223814
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
HUS-Yhtymae, Helsinki · Pohjois-Savon hyvinvointialue, Kuopio · Pohjois-Pohjanmaan hyvinvointialue, Oulu · Tampere University Hospital, Tampere · Varsinais-Suomen hyvinvointialue, Turku
Registry updated 2026-11-06
NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Trial Treatment · Phase 3 · University of Ulm
Helsinki University Central Hospital Meilahden Kolmiosairaala, Helsinki · Tampere University Hospital, Tampere
Registry updated 2026-11-03
2024-512753-24-00
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Trial Treatment · Phase 3 · Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
HUS-Yhtymae, Helsinki · Tampere University Hospital, Tampere
Registry updated 2026-10-21
2023-504999-25-00
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.
HUS-Yhtymae, Helsinki · Pohjois-Savon hyvinvointialue, Kuopio · Oulu University Hospital, Oulu · Pirkanmaan hyvinvointialue, Tampere · Turku University Hospital, Turku
Registry updated 2026-09-23
NCT06652438
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
HUS-Yhtymae, Helsinki · Pohjois-Pohjanmaan hyvinvointialue, Oulu · Tampere University Hospital, Tampere · Varsinais-Suomen hyvinvointialue, Turku
Registry updated 2026-09-02
NCT07719348
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Trial Treatment · Phase 1/2 · Servier
HUS-Yhtymae, Helsinki · Varsinais-Suomen hyvinvointialue, Turku
Registry updated 2026-07-22
NCT07075016
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
FI-Helsinki-HUS, Helsinki · FI-Tampere-TAYS, Tampere
Registry updated 2025-08-19
NCT06262438
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Trial Treatment · Phase 2 · Princess Maxima Center for Pediatric Oncology
HUS-Yhtymae, Helsinki · Pohjois-Savon hyvinvointialue, Kuopio · Oulu University Hospital, Oulu · Pirkanmaan hyvinvointialue, Tampere · Turku University Hospital, Turku
Registry updated 2025-08-05
NCT05477589
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Trial Treatment · Phase 3 · Vastra Gotaland Region
Division of Hematology, Oncology, and Stem Cell Transplantation, The New Children's Hospital, Helsinki University Hospital, Helsinki
Registry updated 2024-12-19
NCT05212103
PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9
Research · Turku University Hospital
Turku University Hospital, Turku PET Centre, Turku
Registry updated 2024-12-04
NCT01828489
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Trial Treatment · Phase 3 · Vaestra Goetalandsregionen
HUS-Yhtymae, Helsinki · Pohjois-Savon hyvinvointialue, Kuopio · Pohjois-Pohjanmaan hyvinvointialue, Oulu · Pirkanmaan hyvinvointialue, Tampere · Varsinais-Suomen hyvinvointialue, Turku
Registry updated 2024-11-22
NCT05431257
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Trial Treatment · Phase 2 · Copenhagen University Hospital, Rigshospitalet
HUS-Yhtymae, Helsinki · Kuopio University Hospital, Kuopio · Oulu University Hospital, Oulu · Tampere University Hospital, Tampere
Registry updated 2022-06-24

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error